Pasithea Therapeutics Statistics
Total Valuation
KTTA has a market cap or net worth of $4.04 million. The enterprise value is -$5.32 million.
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
KTTA has 1.27 million shares outstanding. The number of shares has decreased by -20.66% in one year.
| Current Share Class | 1.27M |
| Shares Outstanding | 1.27M |
| Shares Change (YoY) | -20.66% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 8.78% |
| Owned by Institutions (%) | 1.14% |
| Float | 1.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.19 |
| P/TBV Ratio | 0.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.81
| Current Ratio | 14.81 |
| Quick Ratio | 14.18 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.24% and return on invested capital (ROIC) is -43.32%.
| Return on Equity (ROE) | -68.24% |
| Return on Assets (ROA) | -40.93% |
| Return on Capital (ROIC) | -43.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.97M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.57% in the last 52 weeks. The beta is 0.82, so KTTA's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | -48.57% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 5.67 |
| Relative Strength Index (RSI) | 35.94 |
| Average Volume (20 Days) | 65,870 |
Short Selling Information
The latest short interest is 11,581, so 0.91% of the outstanding shares have been sold short.
| Short Interest | 11,581 |
| Short Previous Month | 22,799 |
| Short % of Shares Out | 0.91% |
| Short % of Float | 1.13% |
| Short Ratio (days to cover) | 0.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -16.14M |
| Pretax Income | -16.28M |
| Net Income | -15.78M |
| EBITDA | -15.49M |
| EBIT | -16.14M |
| Earnings Per Share (EPS) | -$15.14 |
Full Income StatementBalance Sheet
| Cash & Cash Equivalents | 9.36M |
| Total Debt | n/a |
| Net Cash | 9.36M |
| Net Cash Per Share | $7.39 |
| Equity (Book Value) | 17.81M |
| Book Value Per Share | 17.05 |
| Working Capital | 9.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.39 million and capital expenditures $36, giving a free cash flow of -$15.39 million.
| Operating Cash Flow | -15.39M |
| Capital Expenditures | 36 |
| Free Cash Flow | -15.39M |
| FCF Per Share | -$12.15 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |